Literature DB >> 14504797

[Tumescent local anesthesia in proctologic surgery].

D Bussen1, M Sailer, K-H Fuchs, A Thiede.   

Abstract

INTRODUCTION: Tumescent local anesthesia (TLA) was introduced to facilitate liposuction and other procedures mainly in plastic surgery. The aim of our study was to evaluate if this new technique can also be safely applied in proctologic surgery.
METHODS: The following 50 proctologic procedures were performed using TLA as day surgery cases: perianal vein thrombectomy (n=15), subanodermal fistula resection (n=7), anal polyp resection (n=7), fissurectomy ( n=6), perianal abscess revision (n=6), excision of anal skin tags (n=3), hemorrhoidectomy for thrombosed piles (n=3), intersphincteric fistula extirpation (n=1), pilonidal sinus (n=1), and perianal tumor excision (n=1). The subcutaneously infused solution contained 200 ml of Ringer's solution, 50 ml of 2% Mepivacain, and 2.5 ml of epinephrine diluted 1:10,000.
RESULTS: During an average application time of 14.3+/-4.9 min, a mean of 93.1+/-40.7 ml tumescent solution was infused. This dosage resulted in complete pain relief after 18.3+/-5.0 min. Local anesthesia was maintained up to 14 h postoperatively, with a mean duration of 6.7+/-1.9 h. Two patients developed moderate hematomas which required no further treatment.
CONCLUSIONS: Our pilot study demonstrates that slow infusion tumescent local anesthesia can be widely and safely applied in proctologic surgery and enables the performance of these procedures on an outpatient basis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504797     DOI: 10.1007/s00104-003-0670-2

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  8 in total

1.  "Tumescent" liposuction alert: deaths from lidocaine cardiotoxicity.

Authors:  R H de Jong; F M Grazer
Journal:  Am J Forensic Med Pathol       Date:  1999-03       Impact factor: 0.921

2.  High ligation and stripping of the long saphenous vein using the tumescent technique for local anesthesia.

Authors:  T M Proebstle; U Paepcke; G Weisel; S Gass; L Weber
Journal:  Dermatol Surg       Date:  1998-01       Impact factor: 3.398

3.  The role of length of nerve exposed to local anesthetics in impulse blocking action.

Authors:  S A Raymond; S C Steffensen; L D Gugino; G R Strichartz
Journal:  Anesth Analg       Date:  1989-05       Impact factor: 5.108

4.  Fatal outcomes from liposuction: census survey of cosmetic surgeons.

Authors:  F M Grazer; R H de Jong
Journal:  Plast Reconstr Surg       Date:  2000-01       Impact factor: 4.730

5.  Safety of tumescent liposuction in 15,336 patients. National survey results.

Authors:  C W Hanke; G Bernstein; S Bullock
Journal:  Dermatol Surg       Date:  1995-05       Impact factor: 3.398

6.  Antibacterial activity of lidocaine in combination with a bicarbonate buffer.

Authors:  K D Thompson; S Welykyj; M C Massa
Journal:  J Dermatol Surg Oncol       Date:  1993-03

Review 7.  Tumescent technique for regional anesthesia permits lidocaine doses of 35 mg/kg for liposuction.

Authors:  J A Klein
Journal:  J Dermatol Surg Oncol       Date:  1990-03

8.  Epinephrine enhances analgesia produced by epidural bupivacaine during labor.

Authors:  J C Eisenach; S C Grice; D M Dewan
Journal:  Anesth Analg       Date:  1987-05       Impact factor: 5.108

  8 in total
  2 in total

1.  Practicability and patients' subjective experiences of low-dose spinal anaesthesia using hyperbaric bupivacaine for transanal surgery.

Authors:  Marc D Schmittner; Andrea Janke; Christel Weiss; Grietje C Beck; Dieter G Bussen
Journal:  Int J Colorectal Dis       Date:  2009-03-13       Impact factor: 2.571

2.  Randomised clinical trial of pilonidal sinus operations performed in the prone position under spinal anaesthesia with hyperbaric bupivacaine 0.5 % versus total intravenous anaesthesia.

Authors:  Marc D Schmittner; Sven Dieterich; Volker Gebhardt; Christel Weiss; Marc A Burmeister; Dieter G Bussen; Tim Viergutz
Journal:  Int J Colorectal Dis       Date:  2012-11-30       Impact factor: 2.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.